1.Longitudinal observation of an interferon gamma-released assay (T-SPOT.TB) for Mycobacterium tuberculosis infection in AIDS patients on highly active antiretroviral therapy.
Li-fan ZHANG ; Xiao-qing LIU ; Ling-yan ZUO ; Tai-sheng LI ; Guo-hua DENG ; Ai-xia WANG
Chinese Medical Journal 2010;123(9):1117-1121
BACKGROUNDT-SPOT.TB is a novel test for tuberculosis infection with higher sensitivity and specificity than the traditional tuberculin skin test (TST). However, there are no longitudinal data in the literature evaluating T-SPOT.TB for Mycobacterium tuberculosis in patients with acquired immune deficiency syndrome (AIDS) on highly active antiretroviral therapy (HAART). The objective of this study was to assess the value of T-SPOT.TB longitudinally in AIDS patients on HAART without prophylaxis for tuberculosis.
METHODSA prospective observational study was conducted in 50 AIDS patients on HAART. None of the subjects had evidence of active tuberculosis. T-SPOT.TB, a T-cell-based interferon gamma released assay, was performed at the onset of the study and repeated 24 months thereafter. Subjects were evaluated every 6 months during the 36-month follow-up.
RESULTSTwenty-one (42%) AIDS patients on HAART tested positive by T-SPOT.TB (95%CI 28.3% - 55.7%). The pooled spot-forming cells of early secretory antigenic target-6 (ESAT-6) and culture filtrate protein-10 (CFP-10) peptides were 68/million peripheral blood mononuclear cell (PBMC) (interquartile range 44 - 220). The average number of CD4 cells in subjects was (305 +/- 152) cells/microl, and there was no significant difference in T-SPOT.TB response rates between subjects with CD4 cell counts < 200 cells/microl (7/15 (46.7%), 95%CI 21.5% - 71.9%) and those with CD4 cell counts >/= 200 cells/microl (14/35 (40.0%), 95%CI 23.8% - 56.2%, P = 0.662). In the 32 subjects who completed the 24-month follow-up, 10 underwent T-SPOT.TB reversion, one had T-SPOT.TB conversion, six remained positive and 15 remained negative. None of them advanced to active tuberculosis during the 36-month follow-up.
CONCLUSIONThe inactive status of tuberculosis infection may be maintained for a long period in AIDS patients on HAART.
Acquired Immunodeficiency Syndrome ; drug therapy ; immunology ; microbiology ; Adult ; Antiretroviral Therapy, Highly Active ; Female ; Humans ; Interferon-gamma ; secretion ; Male ; Middle Aged ; Mycobacterium tuberculosis ; pathogenicity ; Prospective Studies ; Tuberculosis ; diagnosis ; immunology
2.Kinetics of T-cell-based assays on cerebrospinal fluid and peripheral blood mononuclear cells in patients with tuberculous meningitis.
Ki Ho PARK ; Mi Suk LEE ; Sang Oh LEE ; Sang Ho CHOI ; Yang Soo KIM ; Jun Hee WOO ; Joong Koo KANG ; Sang Ahm LEE ; Sung Han KIM
The Korean Journal of Internal Medicine 2014;29(6):793-799
BACKGROUND/AIMS: The goal of this study was to monitor tuberculosis (TB)-specific T-cell responses in cerebrospinal fluid-mononuclear cells (CSF-MCs) and peripheral blood mononuclear cells (PBMCs) in patients with tuberculous meningitis (TBM) over the course of anti-TB therapy. METHODS: Adult patients (> or = 16 years) with TBM admitted to Asan Medical Center, Seoul, South Korea, were prospectively enrolled between April 2008 and April 2011. Serial blood or CSF samples were collected over the course of the anti-TB therapy, and analyzed using an enzyme-linked immunosorbent spot (ELISPOT) assay. RESULTS: Serial ELISPOT assays were performed on PBMCs from 17 patients (seven definite, four probable, and six possible TBM) and CSF-MC from nine patients (all definite TBM). The median number of interferon-gamma (IFN-gamma)-producing T-cells steadily increased during the first 6 months after commencement of anti-TB therapy in PBMCs. Serial CSF-MC ELISPOT assays revealed significant variability in immune responses during the first 6 weeks of anti-TB therapy, though early increases in CSF-MC ELISPOT results were associated with treatment failure or paradoxical response. CONCLUSIONS: Serial analysis of PBMCs by ELISPOT during the course of treatment was ineffective for predicting clinical response. However, increases in TB-specific IFN-gamma-producing T-cells in CSF-MC during the early phase of anti-TB therapy may be predictive of clinical failure.
Adult
;
Antitubercular Agents/therapeutic use
;
Biological Markers/blood/cerebrospinal fluid
;
*Enzyme-Linked Immunospot Assay
;
Female
;
Humans
;
Interferon-gamma/blood/cerebrospinal fluid
;
*Interferon-gamma Release Tests
;
Kinetics
;
Male
;
Middle Aged
;
Predictive Value of Tests
;
Prospective Studies
;
Republic of Korea
;
T-Lymphocytes/drug effects/*immunology/metabolism/microbiology
;
Treatment Outcome
;
Tuberculosis, Meningeal/blood/cerebrospinal fluid/*diagnosis/drug therapy/immunology/microbiology
3.Clinical characteristics and treatment responses of patients who developed tuberculosis following use of a tumor necrosis factor-alpha inhibitor.
Keun Bum CHUNG ; Eun Young LEE ; Jong Pil IM ; Sung Koo HAN ; Jae Joon YIM
The Korean Journal of Internal Medicine 2013;28(2):174-179
BACKGROUND/AIMS: Individuals being treated with tumor necrosis factor (TNF)-alpha inhibitors are at increased risk of developing tuberculosis (TB). We determined the clinical characteristics and treatment response of patients who developed TB after using TNF-alpha inhibitors. METHODS: Patients with TB detected within 12 months of the initiation of TNF-alpha inhibitor treatment were included, if seen from January 1, 2000 to August 31, 2011. We retrospectively reviewed the clinical records, results of bacteriological examinations, and radiographs of the included patients and the response to anti-TB treatment. RESULTS: We indentified seven cases of TB in 457 patients treated with TNF-alpha inhibitors during the study period. TB developed a median of 123 days (range, 48 to 331) after the first dose of TNF-alpha inhibitor. Pulmonary TB, including TB pleuritis, was diagnosed in three patients and extrapulmonary TB in four. Favorable treatment outcomes were achieved in six of seven patients. CONCLUSIONS: Among the TNF-alpha inhibitor users who contracted TB, extrapulmonary sites were common and the treatment response was satisfactory.
Adult
;
Aged
;
Antitubercular Agents/therapeutic use
;
Female
;
Humans
;
*Immunocompromised Host
;
Immunosuppressive Agents/*adverse effects
;
Interferon-gamma Release Tests
;
Male
;
Middle Aged
;
Retrospective Studies
;
Risk Factors
;
Time Factors
;
Treatment Outcome
;
Tuberculin Test
;
Tuberculosis/diagnosis/drug therapy/*immunology/microbiology
;
Tumor Necrosis Factor-alpha/*antagonists & inhibitors